U.K. to require more disclosure of drug trial data

The tug of war between regulators and drug developers over clinical trial data has been escalating in the UK. Now the government will require developers to turn over data after GlaxoSmithKline was accused of dragging its feet on releasing data indicating that its antidepressant Seroxat is linked to an elevated risk of suicide among teens.

Critics have long contended that Big Pharma companies are notoriously slow about releasing data that could raise concerns about therapies. British authorities say that a tightening of the laws should make that impossible.

Glaxo, meanwhile, has vigorously denied acting improperly over the release of Seroxat data. The suicide risk was only evident after all the trial data was reviewed collectively, says Glaxo, rather than one trial at a time. And once it knew about the danger, adds Glaxo, the company alerted regulators around the world.

- read the article in the Wall Street Journal

Related Articles:
Could full data disclosure avert scandal? Report
UK patients sue for Paxil withdrawal. Report
Study highlights link between Paxil and suicide. Report
Top 10 Drug Warnings and Recalls of 2007. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.